secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-10-17T23:59:59+00:00
Accession:  0001356576-24-000058
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus SPN-820 Phase 2a data: rapid depressive symptom reduction with favorable tolerability
--------------------------------------------------------------------------------

- HAM-D6 score improved -6.1 at 2 hours, -9.6 at Day 10; MADRS improved -16.6 at 4 hours, -22.9 at Day 10.
- Suicidal ideation decreased 80% (from 12.5% to 2.6%) over 10 days.
- SPN-820 well-tolerated; discontinuation rate 2.5% due to AEs; common AEs: headache, nausea, somnolence, dizziness.
- Study enrolled 40 subjects; 38 completed 10-day treatment; open-label, adjunctive to baseline antidepressant.
- Phase 2b double-blind placebo-controlled study topline results expected first-half 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000058/0001356576-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000058/supn-20241017.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer